Summary & Overview

HCPCS J7610: Albuterol Inhalation Solution, Compounded, DME

HCPCS Level II code J7610 denotes a compounded, concentrated albuterol inhalation solution (1 mg) formulated for delivery through durable medical equipment. This code captures a specific medication product and its route of administration, making it relevant for clinicians managing respiratory conditions that require nebulized bronchodilator therapy and for payers processing outpatient and home-based DME medication claims. Nationally, accurate use of J7610 affects billing clarity, coverage determinations, and care continuity for patients requiring compounded inhalation solutions.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for nebulized albuterol compounded products, typical sites of service where DME administration occurs, and the operational billing elements tied to this HCPCS Level II code. The publication also outlines common modifiers and payer considerations where available, benchmark themes for utilization and reimbursement, and any notable policy or coverage updates that influence claims handling.

This resource is intended to help billing staff, revenue cycle managers, and clinical teams understand the purpose and billing scope of J7610, how it fits within DME-supported inhalation therapy workflows, and what to review when submitting or adjudicating claims.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7610HCPCS Level IIalbuterol inhalationcompounded medicationdurable medical equipmentnebulized therapyrespiratory therapyoutpatient billing

Billing Code Overview

HCPCS Level II code J7610 describes albuterol inhalation solution, compounded product, concentrated form, 1 mg, intended for administration through durable medical equipment (DME). This code reflects a compounded respiratory bronchodilator formulation of albuterol delivered as an inhalation solution.

Service type: Respiratory inhalation therapy; compounded medication administration via DME

Typical site of service: Home or outpatient settings where DME is used for aerosolized medication delivery, including patient residences or clinics that provide DME-supported inhalation therapy.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult or pediatric patient with acute bronchospasm from asthma or chronic obstructive pulmonary disease (COPD) presenting to an outpatient infusion center, durable medical equipment (DME) provider clinic, or emergency department observation unit. The treating clinician orders a compounded concentrated form of inhaled albuterol solution (J7610) to be administered via a nebulizer or an auxiliary DME-compatible delivery system for patients who cannot effectively use a metered‑dose inhaler (MDI) with spacer, have severe airflow obstruction requiring continuous or repeated nebulization, or require a customized concentration for body weight or pediatric dosing.

Clinical workflow:

A clinician documents diagnosis and indication for nebulized bronchodilator therapy and writes an order specifying compounded concentrated inhalation albuterol solution (J7610).
Pharmacy compounds the 1 mg concentrated solution per order, verifies stability and compatibility with the patient’s nebulizer/DME, and prepares the labeled unit for administration.
Nursing or respiratory therapy verifies patient identity and airway status, confirms device setup (nebulizer or DME aerosol delivery), and administers the solution per protocol, monitoring vital signs and response.
Post‑administration documentation includes medication given (J7610), dose, route (nebulized via DME), lot and compounding details, patient response, and any adverse events. Billing is submitted using J7610 with appropriate modifiers as applicable and linked to the patient’s ICD‑10 diagnosis codes in the claim.

Typical sites of service: outpatient infusion/respiratory clinic, durable medical equipment provider site, emergency department, urgent care, and inpatient wards for patients requiring nebulized therapy.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	When no additional modifier applies and the service is billed as standard.
`22`	Increased procedural services	When work or resources required for compounding or administration substantially exceed typical requirements.
`23`	Unusual anesthesia	Rarely applicable; use only if anesthesia unrelated to the drug delivery was required (not typical for `J7610`).
`52`	Reduced services	When only a portion of the ordered nebulized treatment was provided.
`53`	Discontinued procedure	When administration is started but discontinued due to patient deterioration or adverse reaction.
`55`	Postoperative management only	Not commonly used for this DME drug but applicable when only postoperative monitoring related to the drug is billed.
`62`	Two surgeons	Not typically used for `J7610`; include only when two qualified professionals share responsibility for a procedural component associated with administration.
`QX`	Services furnished under a physician’s supervision by a PA	When a physician assistant performs the administration under appropriate supervision.
`QY`	Services furnished under a physician’s supervision by a nurse practitioner	When a nurse practitioner performs the administration under appropriate supervision.
`JZ`	No out‑of‑pocket cost to beneficiary (no liability)	When Medicare beneficiary has no liability for the drug cost.
`SH`	Provider administered drug indicator	When the drug is administered in the provider setting as part of outpatient care.
`CQ`	Service furnished by a CRNA	When a certified registered nurse anesthetist is involved in administration (rare for nebulized albuterol).

Taxonomy Code	Specialty	Notes
`207RC0000X`	Pulmonary Disease (Pulmonologist)	Pulmonologists frequently direct nebulized bronchodilator therapy and manage severe airway disease.
`363LF0000X`	Respiratory Therapy	Respiratory therapists perform aerosol drug delivery, device setup, and patient monitoring.
`207Q00000X`	Allergy & Immunology	Allergists manage asthma control plans and prescribe nebulized bronchodilators for severe exacerbations.
`261QA1900X`	Pediatric Medicine	Pediatricians prescribe and coordinate compounded inhalation solutions for children requiring weight‑based dosing.
`207L00000X`	Internal Medicine	Internists manage COPD and asthma in adult patients and coordinate DME-based nebulized therapy.

ICD-10 Code	Description	Clinical Relevance
`J45.901`	Unspecified asthma, uncomplicated	Asthma exacerbations are a primary indication for nebulized albuterol administration.
`J45.909`	Unspecified asthma, uncomplicated (alternate coding)	Commonly used for outpatient asthma needing bronchodilator therapy.
`J44.9`	Chronic obstructive pulmonary disease, unspecified	COPD patients frequently receive nebulized bronchodilators when inhaler use is ineffective.
`J96.00`	Acute respiratory failure, unspecified whether with hypoxia or hypercapnia	Nebulized bronchodilator may be administered as part of acute management for bronchodilatory response.
`R06.2`	Wheezing	Symptom code supporting the medical necessity of bronchodilator therapy.
`R06.3`	Apnea (for select pediatric scenarios)	In infants or critically ill children, nebulized therapy may be part of broader respiratory support.
`J45.21`	Mild intermittent asthma, with (acute) exacerbation	Specific asthma exacerbation codes commonly linked to nebulized bronchodilator use.

CPT Code	Description	Relationship to This Procedure
`94640`	Pressurized or non‑pressurized inhalation treatment for acute airway obstruction; administration of nebulized medication treatment	Commonly used when documenting the actual nebulizer treatment session during which `J7610` is administered.
`94760`	Noninvasive ear, nose and throat, nebulizer/atomizer — initial and subsequent treatments (use varies)	Used in some settings to report nebulizer therapy delivery; crosswalk depends on payer rules.
`94010`	Spirometry, including graphic loop, when performed	Performed before or after nebulized therapy to document objective change in airflow for bronchospasm evaluation.
`94664`	Demonstration and/or evaluation of patient use of an aerosol generator, nebulizer, metered‑dose inhaler or IPPB device	Used when education and device demonstration are provided at the time of dispensing or administration.
`99070`	Supplies and materials (for DME‑administered drugs when not separately billed)	May be used to report non‑routine supplies used during compounded drug administration, subject to payer policy.

OpenPayer